In this video, Dr. Jean Zenklusen describes an NCI tool that enables researchers, clinicians, and patients to access an array of cancer-related data.
In this video, Dr. Jean Zenklusen describes an NCI tool that enables researchers, clinicians, and patients to access an array of cancer-related data.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
2 Commerce Drive
Cranbury, NJ 08512